Cardiff Oncology Inc Dossier
Qualitative Analysis
Business overview
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company focused on developing novel cancer therapies by leveraging Polo-like Kinase 1 (PLK1) inhibition. The company's lead asset is onvansertib, a highly specific, oral PLK1 inhibitor designed to target tumor vulnerabilities, overcome treatment resistance, and deliver superior clinical benefits compared to standard-of-care (SoC) regimens. Onvansertib is currently being evaluated in mid-stage clinical trials for several indications, with its primary focus on first-line (1L) RAS-mutated metastatic colorectal cancer (mCRC). Additionally, onvansertib is being studied in other PLK1-driven cancers through investigator-initiated trials, including chronic myelomonocytic leukemia (CMML), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead clinical asset, onvansertib (a selective oral PLK1 inhibitor), into a Phase 3 registrational trial (CRDF-005) in combination with FOLFIRI and bevacizumab for patients with first-line RAS-mutated metastatic colorectal cancer.
Expected impact: Aims to establish onvansertib as a new standard of care in a market representing approximately 50% of metastatic colorectal cancer patients, potentially unlocking blockbuster sales.
Exploring the therapeutic potential of onvansertib across other solid tumors and hematological indications, including chronic myelomonocytic leukemia (CMML), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and pancreatic cancer, through investigator-initiated studies.
Expected impact: Validates the broader utility of PLK1 inhibition and opens avenues for new development collaborations, licensing deals, or non-dilutive funding.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Pfizer made a $15 million equity investment in Cardiff Oncology and provides strategic support in clinical trial operations. Pfizer Ignite serves as the contract research organization (CRO) managing clinical activities for the CRDF-004 trial. Cardiff retains full global development and commercialization rights to onvansertib.
Terms: $15 million equity investment; Pfizer holds approximately a 3% stake in Cardiff Oncology and previously held right of first access to clinical data (which expired in May 2024).